Skip to Content

Ruxolitinib FDA Approval Status

FDA Approved: No
Generic name: ruxolitinib
Dosage form: Cream
Company: Incyte Corporation
Treatment for: Atopic Dermatitis, Vitiligo

Ruxolitinib is a JAK1/JAK2 inhibitor formulated for topical application in development for the treatment of atopic dermatitis and vitiligo.

Development Timeline for ruxolitinib

DateArticle
Feb 19, 2021Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.